A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Zepbound belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. It contains the active ingredient tirzepatide and comes ...

They're offered in several brand name forms, like Ozempic, where semaglutide is the main substance, or Zepbound, where tirzepatide is the main substance. But they do basically the same thing.